-
Innovation Ranking
NewInnovation Ranking – AIM ImmunoTech Inc
AIM ImmunoTech Inc (AIM ImmunoTech), formerly Hemispherx Biopharma Inc, is an immuno- pharma company. The company focuses on the research and development of therapeutics for the treatment of multiple types of cancers, viruses and immune-deficiency disorders. Its flagship products include Ampligen (rintatolimod) sterile solution which is indicated for the treatment of patients with chronic fatigue syndrome; and Alferon N Injection used for the treatment of refractory or recurrent external condylomata acuminate. The company’s pipeline products are intended to treat various...
-
Product Insights
NewNet Present Value Model: AIM ImmunoTech Inc’s Ampligen
Empower your strategies with our Net Present Value Model: AIM ImmunoTech Inc's Ampligen report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Immunotech Biopharm Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Immunotech Biopharm Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewNet Present Value Model: Aldeyra Therapeutics Inc’s Reproxalap
Empower your strategies with our Net Present Value Model: Aldeyra Therapeutics Inc's Reproxalap report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AD-218 in Hyperlipidemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AD-218 in Hyperlipidemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AD-218 in Hyperlipidemia Drug Details: AD-218 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy For Cytomegalovirus (HHV-5) Infections in Cytomegalovirus (HHV-5) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy For Cytomegalovirus (HHV-5) Infections in Cytomegalovirus (HHV-5) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy For Cytomegalovirus (HHV-5) Infections...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YTE-001 in Hemophagocytic Lymphohistiocytosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YTE-001 in Hemophagocytic Lymphohistiocytosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YTE-001 in Hemophagocytic Lymphohistiocytosis Drug Details: Gene therapy is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – YTE-001 in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YTE-001 in Nasopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YTE-001 in Nasopharyngeal Cancer Drug Details: Gene therapy is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – YTE-001 in Epstein–Barr Virus (HHV-4) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YTE-001 in Epstein–Barr Virus (HHV-4) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YTE-001 in Epstein–Barr Virus (HHV-4) Infections Drug Details: Gene therapy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALG.APV-527 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALG.APV-527 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALG.APV-527 in Solid Tumor Drug Details: ALG.APV-527 is under development for...